198 related articles for article (PubMed ID: 15715492)
1. Synthesis of (+/-)-2-O-[4'-(N-9''-purinyl)butyl] myo-inositol 1,4,5-tris(phosphate), a potent full agonist at the D-myo-inositol 1,4,5-tris(phosphate) receptor.
Moris MA; Caron AZ; Guillemette G; Rognan D; Schmitt M; Schlewer G
J Med Chem; 2005 Feb; 48(4):1251-5. PubMed ID: 15715492
[TBL] [Abstract][Full Text] [Related]
2. Synthesis and binding properties of cyclopentane analogues of myo-inositol 1,4,5-tris(phosphate).
Moris MA; Caron AZ; Guillemette G; Schlewer G
Bioorg Med Chem; 2004 Aug; 12(15):3995-4001. PubMed ID: 15246076
[TBL] [Abstract][Full Text] [Related]
3. Synthesis, acid-base behavior, and binding properties of 6-modified myo-inositol 1,4,5-tris(phosphate)s.
Ballereau S; Guédat P; Poirier SN; Guillemette G; Spiess B; Schlewer G
J Med Chem; 1999 Nov; 42(23):4824-35. PubMed ID: 10579845
[TBL] [Abstract][Full Text] [Related]
4. Synthesis, calcium mobilizing, and physicochemical properties of D-chiro-inositol 1,3,4,6-tetrakisphosphate, a novel and potent ligand at the D-myo-inositol 1,4,5-trisphosphate receptor.
Liu C; Davis RJ; Nahorski SR; Ballereau S; Spiess B; Potter BV
J Med Chem; 1999 Jun; 42(11):1991-8. PubMed ID: 10354407
[TBL] [Abstract][Full Text] [Related]
5. Enantiomers of myo-inositol-1,3,4-trisphosphate and myo-inositol-1,4,6 -trisphosphate: stereospecific recognition by cerebellar and platelet myo-inositol-1,4,5-trisphosphate receptors.
Murphy CT; Bullock AJ; Lindley CJ; Mills SJ; Riley AM; Potter BV; Westwick J
Mol Pharmacol; 1996 Nov; 50(5):1223-30. PubMed ID: 8913354
[TBL] [Abstract][Full Text] [Related]
6. Identification of partial agonists with low intrinsic activity at the inositol-1,4,5-trisphosphate receptor.
Safrany ST; Wilcox RA; Liu C; Dubreuil D; Potter BV; Nahorski SR
Mol Pharmacol; 1993 Apr; 43(4):499-503. PubMed ID: 8386304
[TBL] [Abstract][Full Text] [Related]
7. Dimers of D-myo-inositol 1,4,5-trisphosphate: design, synthesis, and interaction with Ins(1,4,5)P3 receptors.
Riley AM; Laude AJ; Taylor CW; Potter BV
Bioconjug Chem; 2004; 15(2):278-89. PubMed ID: 15025523
[TBL] [Abstract][Full Text] [Related]
8. Molecular recognition at the myo-inositol 1,4,5-trisphosphate receptor. 3-position substituted myo-inositol 1,4,5-trisphosphate analogues reveal the binding and Ca2+ release requirements for high affinity interaction with the myo-inositol 1,4,5-trisphosphate receptor.
Wilcox RA; Challiss RA; Traynor JR; Fauq AH; Ognayanov VI; Kozikowski AP; Nahorski SR
J Biol Chem; 1994 Oct; 269(43):26815-21. PubMed ID: 7929418
[TBL] [Abstract][Full Text] [Related]
9. Molecular recognition of adenophostin, a very potent Ca2+ inducer, at the D-myo-inositol 1,4,5-trisphosphate receptor.
Hotoda H; Murayama K; Miyamoto S; Iwata Y; Takahashi M; Kawase Y; Tanzawa K; Kaneko M
Biochemistry; 1999 Jul; 38(29):9234-41. PubMed ID: 10413497
[TBL] [Abstract][Full Text] [Related]
10. IP3 receptor-ligand. 2: Synthesis and molecular mechanics calculation of adenophostin A.
Hotoda H; Takahashi M; Tanzawa K; Takahashi S; Miyamoto S; Kaneko M
Nucleic Acids Symp Ser; 1995; (34):163-4. PubMed ID: 8841603
[TBL] [Abstract][Full Text] [Related]
11. Synthesis of 1L-chiro-inositol 2,3,5-trisphosphorothioate, the first partial agonist at the platelet myo-inositol 1,4,5-trisphosphate receptor.
Liu C; al-Hafidh J; Westwick J; Potter BV
Bioorg Med Chem; 1994 Apr; 2(4):253-7. PubMed ID: 7922136
[TBL] [Abstract][Full Text] [Related]
12. A systematic study of C-glucoside trisphosphates as myo-inositol trisphosphate receptor ligands. Synthesis of beta-C-glucoside trisphosphates based on the conformational restriction strategy.
Terauchi M; Abe H; Tovey SC; Dedos SG; Taylor CW; Paul M; Trusselle M; Potter BV; Matsuda A; Shuto S
J Med Chem; 2006 Mar; 49(6):1900-9. PubMed ID: 16539376
[TBL] [Abstract][Full Text] [Related]
13. Defining the minimal structural requirements for partial agonism at the type I myo-inositol 1,4,5-trisphosphate receptor.
Wilcox RA; Fauq A; Kozikowski AP; Nahorski SR
FEBS Lett; 1997 Feb; 402(2-3):241-5. PubMed ID: 9037203
[TBL] [Abstract][Full Text] [Related]
14. Synthesis of analogues of myo-inositol 1,4,5-trisphosphate that contain sulfonamide, sulfate, methylphosphonate, and carboxymethyl groups.
Westerduin P; Willems HA; van Boeckel CA
Carbohydr Res; 1992 Oct; 234():131-40. PubMed ID: 1334798
[TBL] [Abstract][Full Text] [Related]
15. Antagonistic effect of inositol pentakisphosphate on inositol triphosphate receptors.
Lu PJ; Shieh WR; Chen CS
Biochem Biophys Res Commun; 1996 Mar; 220(3):637-42. PubMed ID: 8607817
[TBL] [Abstract][Full Text] [Related]
16. myo-inositol 1,4,6-trisphosphorothioate and myo-inositol 1,3, 6-trisphosphorothioate: partial agonists with very low intrinsic activity at the platelet myo-inositol 1,4,5-trisphosphate receptor.
Murphy CT; Riley AM; Mills SJ; Lindley CJ; Potter BV; Westwick J
Mol Pharmacol; 2000 Mar; 57(3):595-601. PubMed ID: 10692501
[TBL] [Abstract][Full Text] [Related]
17. C-glycoside based mimics of D-myo-inositol 1,4,5-trisphosphate.
Rosenberg HJ; Riley AM; Correa V; Taylor CW; Potter BV
Carbohydr Res; 2000 Oct; 329(1):7-16. PubMed ID: 11086681
[TBL] [Abstract][Full Text] [Related]
18. GATA4-mediated cardiac hypertrophy induced by d-myo-inositol 1,4,5-tris-phosphate.
Zhu Z; Zhu S; Liu D; Yu Z; Yang Y; van der Giet M; Tepel M
Biochem Biophys Res Commun; 2005 Dec; 338(2):1236-40. PubMed ID: 16259952
[TBL] [Abstract][Full Text] [Related]
19. Pretreatment with D-myo-inositol trisphosphate reduces infarct size in rabbit hearts: role of inositol trisphosphate receptors and gap junctions in triggering protection.
Przyklenk K; Maynard M; Darling CE; Whittaker P
J Pharmacol Exp Ther; 2005 Sep; 314(3):1386-92. PubMed ID: 15919762
[TBL] [Abstract][Full Text] [Related]
20. D-myo-inositol-1,4,5-trisphosphate and adenophostin mimics: importance of the spatial orientation of a phosphate group on the biological activity.
Roussel F; Moitessier N; Hilly M; Chrétien F; Mauger JP; Chapleur Y
Bioorg Med Chem; 2002 Mar; 10(3):759-68. PubMed ID: 11814866
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
